Advertisement
Screener

aTYR PHARMA INC (ATYR) Increase (Decrease) in Other Receivables

2.8 / 5 stars · 68/120 Roast Me

aTYR PHARMA INC Increase (Decrease) in Other Receivables

aTYR PHARMA INC (ATYR) reported Increase (Decrease) in Other Receivables of -$455.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherReceivables · last filed 2026-08-07

  • aTYR PHARMA INC increase (decrease) in other receivables for the quarter ending 2026-06-30 was -$59.00K.
  • aTYR PHARMA INC increase (decrease) in other receivables for the quarter ending 2026-03-31 was -$396.00K.
  • aTYR PHARMA INC increase (decrease) in other receivables for the quarter ending 2025-12-31 was -$169.00K.
  • aTYR PHARMA INC increase (decrease) in other receivables for the quarter ending 2025-09-30 was $544.00K, a 167.98% increase year-over-year.
  • aTYR PHARMA INC increase (decrease) in other receivables for fiscal 2025 was -$863.00K.
  • aTYR PHARMA INC increase (decrease) in other receivables for fiscal 2024 was -$402.00K.
  • aTYR PHARMA INC increase (decrease) in other receivables for fiscal 2023 was -$9.05M, a 175.94% decline from fiscal 2022.
  • aTYR PHARMA INC increase (decrease) in other receivables for fiscal 2022 was $11.92M.
Period endIncrease (Decrease) in Other Receivables 3 monthIncrease (Decrease) in Other Receivables 6 monthIncrease (Decrease) in Other Receivables 9 monthIncrease (Decrease) in Other Receivables 12 month
2026-06-30-$59.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07
-$455.00K
10-Q · filed 2026-08-07
-$624.00K
derived: sum of 3 quarters · filed 2026-08-07
-$80.00K
derived: sum of 4 quarters · filed 2026-08-07
2026-03-31-$396.00K
10-Q · filed 2026-05-15
-$565.00K
derived: sum of 2 quarters · filed 2026-05-15
-$21.00K
derived: sum of 3 quarters · filed 2026-05-15
-$511.00K
derived: sum of 4 quarters · filed 2026-08-07
2025-12-31-$169.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
$375.00K
derived: sum of 2 quarters · filed 2026-03-05
-$115.00K
derived: sum of 3 quarters · filed 2026-08-07
-$863.00K
10-K · filed 2026-03-05
2025-09-30$544.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$54.00K
derived: sum of 2 quarters · filed 2026-08-07
-$694.00K
10-Q · filed 2025-11-06
-$789.00K
derived: sum of 4 quarters · filed 2026-08-07
2025-06-30-$490.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07
-$1.24M
10-Q · filed 2026-08-07
-$1.33M
derived: sum of 3 quarters · filed 2026-08-07
-$1.13M
derived: sum of 4 quarters · filed 2026-08-07
2025-03-31-$748.00K
10-Q · filed 2026-05-15
-$843.00K
derived: sum of 2 quarters · filed 2026-05-15
-$640.00K
derived: sum of 3 quarters · filed 2026-05-15
-$696.00K
derived: sum of 4 quarters · filed 2026-05-15
2024-12-31-$95.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
$108.00K
derived: sum of 2 quarters · filed 2026-03-05
$52.00K
derived: sum of 3 quarters · filed 2026-03-05
-$402.00K
10-K · filed 2026-03-05
2024-09-30$203.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$147.00K
derived: sum of 2 quarters · filed 2025-11-06
-$307.00K
10-Q · filed 2025-11-06
$151.00K
derived: sum of 4 quarters · filed 2026-03-05
2024-06-30-$56.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
-$510.00K
10-Q · filed 2025-08-07
-$52.00K
derived: sum of 3 quarters · filed 2026-03-05
$990.00K
derived: sum of 4 quarters · filed 2026-03-05
2024-03-31-$454.00K
10-Q · filed 2025-05-07
$4.00K
derived: sum of 2 quarters · filed 2026-03-05
$1.05M
derived: sum of 3 quarters · filed 2026-03-05
$375.00K
derived: sum of 4 quarters · filed 2026-03-05
2023-12-31$458.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
$1.50M
derived: sum of 2 quarters · filed 2026-03-05
$829.00K
derived: sum of 3 quarters · filed 2026-03-05
-$9.05M
10-K · filed 2026-03-05
2023-09-30$1.04M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
$371.00K
derived: sum of 2 quarters · filed 2024-11-07
-$9.51M
10-Q · filed 2024-11-07
$2.48M
derived: sum of 4 quarters · filed 2025-03-13
2023-06-30-$671.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13
-$10.55M
10-Q · filed 2024-08-13
$1.44M
derived: sum of 3 quarters · filed 2025-03-13
$1.38M
derived: sum of 4 quarters · filed 2025-03-13
2023-03-31-$9.88M
10-Q · filed 2024-05-02
$2.11M
derived: sum of 2 quarters · filed 2025-03-13
$2.05M
derived: sum of 3 quarters · filed 2025-03-13
$2.05M
derived: sum of 4 quarters · filed 2025-03-13
2022-12-31$11.99M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13
$11.93M
derived: sum of 2 quarters · filed 2025-03-13
$11.93M
derived: sum of 3 quarters · filed 2025-03-13
$11.92M
10-K · filed 2025-03-13
2022-09-30-$61.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
-$61.00K
derived: sum of 2 quarters · filed 2023-11-09
-$70.00K
10-Q · filed 2023-11-09
$236.00K
derived: sum of 4 quarters · filed 2024-03-14
2022-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09
-$9.00K
10-Q · filed 2023-08-09
$297.00K
derived: sum of 3 quarters · filed 2024-03-14
$336.00K
derived: sum of 4 quarters · filed 2024-03-14
2022-03-31-$9.00K
10-Q · filed 2023-05-09
$297.00K
derived: sum of 2 quarters · filed 2024-03-14
$336.00K
derived: sum of 3 quarters · filed 2024-03-14
$337.00K
derived: sum of 4 quarters · filed 2024-03-14
2021-12-31$306.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14
$345.00K
derived: sum of 2 quarters · filed 2024-03-14
$346.00K
derived: sum of 3 quarters · filed 2024-03-14
-$1.60M
10-K · filed 2024-03-14
2021-09-30$39.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
$40.00K
derived: sum of 2 quarters · filed 2022-11-14
-$1.91M
10-Q · filed 2022-11-14
-$116.00K
derived: sum of 4 quarters · filed 2023-03-14
2021-06-30$1.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15
-$1.95M
10-Q · filed 2022-08-15
-$155.00K
derived: sum of 3 quarters · filed 2023-03-14
-$741.00K
derived: sum of 4 quarters · filed 2023-03-14
2021-03-31-$1.95M
10-Q · filed 2022-05-10
-$156.00K
derived: sum of 2 quarters · filed 2023-03-14
-$742.00K
derived: sum of 3 quarters · filed 2023-03-14
$37.00K
derived: sum of 4 quarters · filed 2023-03-14
2020-12-31$1.79M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14
$1.21M
derived: sum of 2 quarters · filed 2023-03-14
$1.99M
derived: sum of 3 quarters · filed 2023-03-14
$1.94M
10-K · filed 2023-03-14
2020-09-30-$586.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12
$193.00K
derived: sum of 2 quarters · filed 2021-11-12
$145.00K
10-Q · filed 2021-11-12
$188.00K
derived: sum of 4 quarters · filed 2022-03-15
2020-06-30$779.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11
$731.00K
10-Q · filed 2021-08-11
$774.00K
derived: sum of 3 quarters · filed 2022-03-15
$736.00K
derived: sum of 4 quarters · filed 2022-03-15
2020-03-31-$48.00K
10-Q · filed 2021-05-14
-$5.00K
derived: sum of 2 quarters · filed 2022-03-15
-$43.00K
derived: sum of 3 quarters · filed 2022-03-15
2019-12-31$43.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15
$5.00K
derived: sum of 2 quarters · filed 2022-03-15
-$58.00K
10-K · filed 2022-03-15
2019-09-30-$38.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13
-$101.00K
10-Q · filed 2020-11-13
2019-06-30-$63.00K
10-Q · filed 2020-08-13
2018-12-31$53.00K
10-K · filed 2021-03-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
Quince Therapeutics, Inc. (QNCX)United States$0.031B
CEL SCI CORP (CVM)United States$0.030B-0.81
Scilex Holding Co (SCLX)United States$0.042B-0.14
Metagenomi Therapeutics, Inc. (MGX)United States$0.044B-0.48
Estrella Immunopharma, Inc. (ESLA)United States$0.020B
LeonaBio, Inc. (LONA)United States$0.047B-0.61
Jasper Therapeutics, Inc. (JSPR)United States$0.020B-0.37
Instil Bio, Inc. (TIL)United States$0.048B-1.73
Tevogen Inc. (TVGN)United States$0.049B
BioCardia, Inc. (BCDA)United States$0.016B